GlassScriptPhysician profile
Manik Singh
NPI 1871765826
$1,902.76
in general payments reported to CMS, 2019-2025
14 companies · $238 in 2025
The $238 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $784 · 2020: $180 · 2021: $194 · 2022: $271 · 2023: $146 · 2024: $89.26 · 2025: $238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $474.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $473.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tosoh Bioscience, INC. | $758.00 | 2019 | |
| Novo Nordisk INC | $377.01 | 2019-2025 | |
| Bioventus LLC | $245.01 | 2021-2025 | Durolane, Gelsyn-3, L360 Thigh System |
| Glaxosmithkline, LLC. | $176.98 | 2021-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Lilly USA, LLC | $72.91 | 2020-2023 | Jardiance |
| Genentech USA, INC. | $57.13 | 2020-2021 | |
| Daiichi Sankyo INC. | $45.30 | 2021 | |
| Amgen INC. | $42.55 | 2021-2025 | Otezla, Repatha |
| Depuy Synthes Sales INC. | $42.16 | 2021-2024 | Orthovisc |
| Exact Sciences Corporation | $24.43 | 2025 | The Cologuard Plus Collection Kit |
| Pfizer INC. | $16.48 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $16.25 | 2025 | Farxiga |
| Esperion Therapeutics, INC. | $15.00 | 2021 | |
| Idorsia Pharmaceuticals US INC | $13.55 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manik Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.